Literature DB >> 29025553

Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis.

Christoph Gräni1, Christian Eichhorn1, Loïc Bière1, Venkatesh L Murthy2, Vikram Agarwal3, Kyoichi Kaneko1, Sarah Cuddy1, Ayaz Aghayev3, Michael Steigner3, Ron Blankstein4, Michael Jerosch-Herold3, Raymond Y Kwong5.   

Abstract

BACKGROUND: Diagnosing myocarditis is challenged by nonspecific clinical signs and symptoms and low accuracy of endomyocardial biopsy. Cardiac magnetic resonance imaging (CMR) provides both cardiac anatomy and tissue characterization in this setting, but the prognostic value of this method as a primary assessment tool in patients with suspected myocarditis remains limited.
OBJECTIVES: This study sought to determine cardiac event-free survival of a consecutive cohort with suspected myocarditis with regard to CMR findings.
METHODS: Six hundred seventy patients with suspected myocarditis underwent CMR including late gadolinium enhancement (LGE) parameters between 2002 and 2015 and were included and followed. We performed multivariable model for major adverse cardiovascular events (MACE) and determined the continuous net reclassification improvement by LGE markers.
RESULTS: At a median follow-up of 4.7 years (interquartile range [IQR]: 2.3 to 7.3 years), 98 patients experienced a MACE. Two hundred ninety-four (44%) patients showed LGE presence, which was associated with a more than doubling risk of MACE (hazard ratio [HR]: 2.22; 95% confidence interval [CI]: 1.47 to 3.35; p < 0.001). Annualized MACE rates were 4.8% and 2.1% corresponding to LGE presence and absence, respectively (p < 0.001). In the multivariable model, LGE presence maintained significant association with MACE (HR: 1.72; 95% CI: 1.08 to 2.76; p = 0.023). The computed continuous net reclassification improvement was 0.39 (95% CI: 0.10 to 0.67) when LGE presence was added to the multivariable model for MACE. Regarding location and pattern, septal and midwall LGE showed strongest associations with MACE (HR: 2.55; 95% CI: 1.77 to 3.83 and HR: 2.39; 95% CI: 1.54 to 3.69, respectively; both p < 0.001). A patchy distribution portended to a near 3-fold increased hazard to MACE (HR: 2.93; 95% CI: 1.79 to 4.80; p < 0.001). LGE extent (per 10% increase) corresponded to a 79% increase in risk of MACE (HR: 1.79; 95% CI: 1.25 to 2.57; p = 0.002). A normal CMR study corresponded to low annual MACE and death rates of 0.8% and 0.3%, respectively.
CONCLUSIONS: CMR tissue characterization provides effective risk stratification in patients with suspected myocarditis.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CMR; cardiovascular magnetic resonance imaging; extracellular volume; myocarditis; outcome

Mesh:

Year:  2017        PMID: 29025553      PMCID: PMC6506846          DOI: 10.1016/j.jacc.2017.08.050

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  102 in total

Review 1.  Cardiotoxicity of Immune Checkpoint Inhibitors.

Authors:  Lili Zhang; Maeve Jones-O'Connor; Magid Awadalla; Daniel A Zlotoff; Paaladinesh Thavendiranathan; John D Groarke; Alexandra-Chloe Villani; Alexander R Lyon; Tomas G Neilan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-06-08

Review 2.  Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients.

Authors:  Srilakshmi Vallabhaneni; Kathleen W Zhang; Jose A Alvarez-Cardona; Joshua D Mitchell; Henning Steen; Pamela K Woodard; Daniel J Lenihan
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-12       Impact factor: 2.357

Review 3.  Advances in MRI Applications to Diagnose and Manage Cardiomyopathies.

Authors:  Ramya Vajapey; Brendan Eck; Wilson Tang; Deborah H Kwon
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

4.  Computational Identification of Ventricular Arrhythmia Risk in Pediatric Myocarditis.

Authors:  Mark J Cartoski; Plamen P Nikolov; Adityo Prakosa; Patrick M Boyle; Philip J Spevak; Natalia A Trayanova
Journal:  Pediatr Cardiol       Date:  2019-03-06       Impact factor: 1.655

5.  Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Sarju Ganatra; Tomas G Neilan
Journal:  Oncologist       Date:  2018-05-25

6.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

Review 7.  Diagnostic and prognostic role of cardiac magnetic resonance in acute myocarditis.

Authors:  Chrysanthos Grigoratos; Gianluca Di Bella; Giovanni Donato Aquaro
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

8.  Persistence of Late Gadolinium Enhancement on Follow-Up CMR Imaging in Children with Acute Myocarditis.

Authors:  Siddharth Dubey; Arpit Agarwal; Stephanie Nguyen; Dilachew Adebo
Journal:  Pediatr Cardiol       Date:  2020-09-12       Impact factor: 1.655

9.  The Prognostic Role of Tissue Characterisation using Cardiovascular Magnetic Resonance in Heart Failure.

Authors:  Robert D Adam; James Shambrook; Andrew S Flett
Journal:  Card Fail Rev       Date:  2017-11

Review 10.  Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment.

Authors:  Enrico Ammirati; Giacomo Veronese; Manlio Cipriani; Francesco Moroni; Andrea Garascia; Michela Brambatti; Eric D Adler; Maria Frigerio
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.